5yr
View our preview of the 2021 American Society of Clinical Oncology (ASCO) Conference
KRAS Oncogene Connect
5yr
KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34012925/
Lung cancer, the leading cause of cancer-related deaths worldwide, can be classified into small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC is the most common histological type,...
-
Naveed Saleh, MD, MS – Skipta Team5yrKey Points • In the current review article, authors assessed the pathogenesis, treatment status, progress of immunotherapy, and targeted therapy of KRAS-mutant NSCLC . • In particular, they stressed promising new treatments Show More
5yr
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33972557/
Understanding resistance mechanisms to targeted therapies and immune checkpoint blockade in mutant KRAS lung cancers is critical to developing novel combination therapies and improving patient survival. Here, we show that...
-
Naveed Saleh, MD, MS – Skipta Team5yrKey Points • In the current preclinical trial, researchers demonstrated that in mutant KRAS lung tumors, MEK inhibition promoted PD-L1 expression, whereas PD-L1 blockade upregulated MAPK signaling. Combined MEK inhibition with Show More
5yr
Rational antibody design for undruggable targets using kinetically controlled biomolecular probes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33863724/
1 Oblique Therapeutics AB, SE-41346 Gothenburg, Sweden. 2 Department of Physiology and Pharmacology, Karolinska Institutet, SE-171 77 Stockholm, Sweden. 3 Nanoxis Consulting AB, SE-40016 Gothenburg, Sweden. 4 Integrative Research Laboratories,...
5yr
Simultaneous Identification of EGFR,KRAS,ERBB2, and TP53 Mutations in Patients with Non-Small Cell Lung Cancer by Machine Learning-Derived Three-Dimensional Radiomics - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33920322/
Machine learning-derived 3D radiomics can simultaneously discriminate the presence of EGFR , KRAS , ERBB2 , and TP53 mutations in patients with NSCLC. This noninvasive and low-cost approach may be...